SERTINDOLE AND RISPERIDONE IN TREATMENT RESISTANT SCHIZOPHRENIC PATIENTS

舍吲哚和利培酮治疗难治性精神分裂症患者

• 批准号: 6276522
• 负责人: Peter F Buckley
• 金额: $ 1.83万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276522
• 关键词: antipsychotic agents; clinical research; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; limbic system; mental disorder chemotherapy; risperidone; schizophrenia; serotonin inhibitor

The objective of this study is to examine the efficacy and safety of sertindole compared to risperidone when administered to treatment resistant schizophrenic patients. According to the dopamine hypothesis of schizophrenia, the antipsychotic effects of neuroleptic drugs are due to blockade of dopamine D2- receptors in the mesolimbic pathway. The blocking of dopamine receptors in the nigrostriatal pathway is thought to be responsible for the appearance of extrapyramidal adverse events. Most currently available antipsychotics block the action of dopamine receptors nonselectively in both pathways. Consequently, a high incidence of extrapyramidal adverse events is seen together with the antipsychotic activity of these drugs. Sertindole (Abbott-81968), combines a selective antagonist effect on mesolimbic dopamine neurons with seratonergic antagonist effects. The compound has no significant effect at relevant doses on nigostriatal dopamine neurons in in vivo animal experiments. Sertindole might be expected to improve symptoms of schizophrenia with minimal or no neurological adverse events. Twenty subjects are expected to participate at this site, 400 in North America.

这项研究的目的是检查 与利培酮进行治疗相比 抗性精神分裂症患者。 根据精神分裂症的多巴胺假说，抗精神病药 神经药物的作用是由于多巴胺D2-封锁而引起的 中左右途径中的受体。 多巴胺受体的阻断 在黑质纹状体中被认为是负责 锥体外不良事件的出现。 当前最可用的 抗精神病药阻止了多巴胺受体在非脑中的作用 这两个途径。 因此，高锥体室外不良发生率 事件与这些药物的抗精神病药一起观察到。 Sertindole（Abbott-81968），结合了选择性拮抗剂对 伴有血清能拮抗剂作用的中唇多巴胺神经元。 这 化合物在相关剂量上没有显着作用对杀伤剂的作用 体内动物实验中的多巴胺神经元。 Sertindole可能是 预计将改善精神分裂症的症状，而不是 神经不良事件。 预计有20个受试者 参加北美400个地点。